Experiments in vivo indicated that tumor growth and metastasis were reduced by FAK inhibitor in breast cancer mouse model, human glioblastoma xenografted model and adenocarcinoma xenograft model (Brown et al., 2018; Hirt et al., 2018; Tiede et al., 2018). This evidence concerns the gene PTK2 and adenocarcinoma.